Wise summarizes survival data of ARASENS and PEACE-1 in prostate cancer


welcome to OncLive on the air®! I’m your host today, Caroline Seymour.

OncLive on the air® is a podcast by Live®, which provides oncology professionals with the resources and information they need to provide the best patient care. In digital and printed format, Live® covers all aspects of oncology practice, from new technologies to therapeutic advances to important regulatory decisions.

In today’s episode, we had the pleasure of speaking with David R. Wise, MD, PhD. Dr. Wise is an assistant professor in the Department of Medicine and the Department of Urology at NYU Grossman School of Medicine, part of NYU Langone Health.

In our exclusive interview, Dr. Wise discussed the practice-changing results from the ARASENS (NCT02799602) and PEACE1 (NCT01957436) Phase 3 trials. The ARASENS study investigated darolutamide (Nubeqa) combined with androgen deprivation therapy (ADT) and docetaxel in metastatic castration-sensitive prostate cancer. The triplet resulted in a 32.5% reduction in the risk of death compared to docetaxel and ADT alone. Additionally, during a 36-week follow-up, this trial demonstrated a 63% reduction in the risk of death in patients with undetectable prostate-specific antigen levels who received the darolutamide combination.

In the PEACE1 trial, the combination of ADT, docetaxel, abiraterone acetate (Zytiga) and radiotherapy showed a statistically significant improvement in overall survival (OS) and radiographic PFS ( rPFS) in patients with hormone-naïve metastatic prostate cancer. The median rPFS in patients treated with the combination was 4.46 years compared to 2.22 years in patients who did not receive abiraterone.

Dr. Wise highlighted how intensive treatment with dual or triple therapy can lead to better long-term outcomes in prostate cancer. He also described potential treatment sequencing options with the variety of agents available in this setting and discussed the importance of communication between patients and physicians so that patients can receive optimal care tailored to their needs. .


That’s all we have for today! Thanks for listening to this episode of OncLive on the air®. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the field of oncology.

For more oncology updates, be sure to visit www.OncLive.com and sign up for our e-newsletters.

Live® is also on social media. On Twitter, follow us on @OncLive and @OncLiveSOSS. On Facebook, like us at OncLive and OncLive State of the Science Summit and follow our OncLive page on LinkedIn.

If you liked today’s episode of OncLive on the air®, please consider subscribing to our podcast on Apple Podcasts, Spotify, Google Podcasts, Amazon Music and many of your other favorite podcast platforms*, to receive a notification whenever a new episode is released. While you’re at it, please take a moment to rate us!

Thanks again for listening OncLive on the air®.

*Live live® is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic and TuneIn.


About Author

Comments are closed.